Skip to content S&P 500 6,791.80 -1.03% Dow Jones 47,085.60 -0.57% Nasdaq 100 25,649.20 -1.39% Russell 2000 2,441.33 -1.45% FTSE 100 9,660.60 -0.55% Nikkei 225 51,378.70 -2.19% Home >Investing >Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (November 2025) Shares of Pfizer (NYSE: PFE)Â lost 9.90% over the past month after gaining 10.02% the month prior. The stock's year-to-date loss now stands at 7.33%. Over the past year, PFE has fallen by 11.17%. The recent rally in the Big Pharma stock c ...

Group 1: Pfizer - Pfizer's stock has decreased by approximately 62% from its pandemic highs, yet it offers a high dividend yield of 7.3% [4] - The company's adjusted earnings per share fell from $6.58 in 2022 to $3.11 last year due to declining demand for COVID-19 vaccines and treatments [4][5] - Pfizer anticipates a 6.8% decline in adjusted earnings for the current year, with a projected low of $2.80 per share, which is sufficient to support its annual dividend of $1.72 [5] - The drug Eliquis, which accounts for 14% of Pfizer's revenue, is expected to face competition from generics starting in 2028 [6] - Despite facing patent cliffs, Pfizer has a strong development pipeline, with over a dozen FDA approvals last year, indicating potential for continued dividend growth [7] Group 2: Prologis - Prologis has capitalized on the surge in e-commerce demand, becoming the largest real estate investment trust (REIT) available to everyday investors [8] - The stock has declined by about 12% from its March peak, currently offering a 3.7% yield [8] - Prologis has increased its dividend by 11.7% annually over the past five years, suggesting potential for double-digit yield on cost for investors in less than a decade [9] - Major customers include Amazon, Home Depot, and FedEx, but these tenants only account for 8.2% of total rent payments, showcasing strong diversification [9] - Prologis holds an A2 rating from Moody's and an A rating from S&P Global, with a low average interest rate of 3.1% on its debts [10] - The company can offer competitive rates to smaller competitors and is positioned for continued growth by acquiring and leasing back logistics real estate [11] Group 3: Investment Comparison - Pfizer offers a nearly double yield compared to Prologis, but its dividend growth rate is less than half that of Prologis [12] - For investors nearing retirement, Pfizer may be appealing, while Prologis is suggested as a better option for income-seeking investors [12]